TAA-T

TAA-T is an autologous or allogeneic T-cell immunotherapy developed by the Children's National Research Institute for the treatment of relapsed or refractory solid tumors. The therapy consists of ex vivo expanded cytotoxic T lymphocytes (CTLs) specifically trained to target three tumor-associated antigens (TAAs): Wilms tumor protein (WT1), melanoma antigen preferentially expressed in tumors (PRAME), and survivin (BIRC5). Unlike CAR-T therapies that use genetic modification, TAA-T products are generated by stimulating a patient's (autologous) or a donor's (allogeneic/HLA-matched) peripheral blood mononuclear cells with antigen-presenting cells pulsed with pepmixes covering the target antigens. This approach aims to provide a broad anti-tumor response while minimizing off-target toxicity. In Phase I trials, the therapy has demonstrated safety and signs of clinical activity, including disease stabilization and progression-free survival in pediatric and adult patients with high-risk solid tumors.

Other names

Tumor-associated antigen-specific T cellsMulti-tumor associated antigen-specific T cellsMulti-TAA-specific T cellsTumor-associated antigen-specific cytotoxic T lymphocytes